Version May 2024
| Cancer type | Recommendation |
| Breast | Women 50 to 69 years: annual screening mammography with or without clinical breast examination; age 40 to 49 years: the benefit of screening is less certain and should be left to the decision of the clinician and patient; ≥70 years of age: annual screening is appropriate as long as estimated life exectancy is ≥8 years. |
| Skin | Monthly self-examination; clinician examination annually, with early referral for suspected lesions. |
| Cervical | All women ≥18 years old and sexually active girls <18 years old should undergo an annual pelvic examination and Pap smear. |
| Anogenital | Yearly physical examination of the anogenital area, including pelvic examination and cytologic studies for women. Insufficient evidence to recommend for or against screening anoscopy and biopsies of anal epithelium. |
| KS/other sarcomas | Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening. |
| Prostate | Annual screening with digital rectal examination and PSA recommended for men ≥age 50 years if their estimated life expectancy is at least 10 years. If positive family history or African-American race, may start annual screening earlier (eg, age 45 years). |
| Colorectal | Starting at age 45 years: annual FOBT and either sigmoidoscopy every five years or colonoscopy every 10 years*. |
| PTLD | Complete history and physical examination every three months, particularly in the first posttransplant year; patients at increased risk of PTLND may benefit from more frequent screening. |
| Lung | Not recommended. |
| HCC | For patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound every 6 to 12 months. |
| Renal cell | Screening via cytologic or radiographic means is not recommended, except possibly for patients with a history of analgesic abuse. |
KS: Kaposi sarcoma; PSA: prostate specific antigen; HHV-8: human herpesvirus 8; FOBT: fecal occult blood testing; PTLD: posttransplant lymphoproliferative disorder; HCC: hepatocellular cancer; AFP: alpha-fetoprotein.
* At some institutions, screening is started at age 40 years or five years after transplant, whichever comes first.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
